Q1 Earnings Estimate for Neurogene Issued By William Blair

Neurogene Inc. (NASDAQ:NGNE) – William Blair issued their Q1 2026 earnings estimates for Neurogene in a note issued to investors on Tuesday, March 25th. William Blair analyst S. Corwin anticipates that the company will post earnings of ($1.18) per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. William Blair also issued estimates for Neurogene’s Q2 2026 earnings at ($1.11) EPS, Q3 2026 earnings at ($1.14) EPS and Q4 2026 earnings at ($1.16) EPS.

Separately, HC Wainwright decreased their price objective on Neurogene from $55.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $59.80.

Neurogene Stock Up 1.7 %

Neurogene stock opened at $14.20 on Wednesday. Neurogene has a 12-month low of $13.47 and a 12-month high of $74.49. The stock has a 50-day simple moving average of $17.01 and a 200 day simple moving average of $29.15.

Neurogene (NASDAQ:NGNE) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.99) EPS for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.05. The firm had revenue of $0.93 million during the quarter.

Insider Buying and Selling at Neurogene

In related news, CFO Christine Mikail Cvijic sold 4,501 shares of Neurogene stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $16.94, for a total value of $76,246.94. Following the sale, the chief financial officer now owns 72,343 shares of the company’s stock, valued at approximately $1,225,490.42. This trade represents a 5.86 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 9.92% of the company’s stock.

Institutional Trading of Neurogene

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Barclays PLC increased its position in shares of Neurogene by 319.4% during the 3rd quarter. Barclays PLC now owns 14,859 shares of the company’s stock worth $623,000 after purchasing an additional 11,316 shares during the last quarter. FMR LLC boosted its position in shares of Neurogene by 912.4% in the third quarter. FMR LLC now owns 731,801 shares of the company’s stock valued at $30,706,000 after acquiring an additional 659,515 shares during the period. Franklin Resources Inc. bought a new position in shares of Neurogene during the third quarter worth approximately $296,000. State Street Corp grew its holdings in shares of Neurogene by 17.5% during the 3rd quarter. State Street Corp now owns 246,540 shares of the company’s stock worth $10,345,000 after purchasing an additional 36,687 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in Neurogene in the 3rd quarter valued at about $324,000. 52.37% of the stock is currently owned by institutional investors and hedge funds.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.